blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2968564

EP2968564 - COMBINATIONS OF INHIBITORS OF MEK, EGFR AND ERBB2 IN THE TREATMENT OF KRAS-MUTANT LUNG CANCER [Right-click to bookmark this link]
Former [2016/03]COMBINATIONS OF INHIBITORS OF MEK, EGFR AND ERBB2 IN THE TREATMENT OF KRAS-MUTANT LUNG CANCER AND KRAS-MUTANT COLON CANCER
[2017/50]
StatusNo opposition filed within time limit
Status updated on  13.03.2020
Database last updated on 19.10.2024
FormerThe patent has been granted
Status updated on  05.04.2019
FormerGrant of patent is intended
Status updated on  12.06.2018
FormerExamination is in progress
Status updated on  22.05.2018
FormerGrant of patent is intended
Status updated on  18.01.2018
FormerExamination is in progress
Status updated on  18.12.2017
FormerGrant of patent is intended
Status updated on  06.12.2017
FormerExamination is in progress
Status updated on  02.12.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis
Plesmanlaan 121
1066 CX Amsterdam / NL
[2019/19]
Former [2016/03]For all designated states
Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis
Plesmanlaan 121
1066 CX Amsterdam / NL
Inventor(s)01 / SUN, Chong
121 Plesmanlaan
1066 CX Amsterdam / NL
02 / BERNARDS, Rene
121 Plesmanlaan
1066 CX Amsterdam / NL
 [2016/03]
Representative(s)Algemeen Octrooi- en Merkenbureau B.V.
P.O. Box 645
5600 AP Eindhoven / NL
[2019/19]
Former [2016/03]EP&C
P.O. Box 3241
2280 GE Rijswijk / NL
Application number, filing date14714409.112.03.2014
[2016/03]
WO2014NL50148
Priority number, dateNL2013201044012.03.2013         Original published format: NL 2010440
[2016/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014142660
Date:18.09.2014
Language:EN
[2014/38]
Type: A1 Application with search report 
No.:EP2968564
Date:20.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 18.09.2014 takes the place of the publication of the European patent application.
[2016/03]
Type: B1 Patent specification 
No.:EP2968564
Date:08.05.2019
Language:EN
[2019/19]
Search report(s)International search report - published on:EP18.09.2014
ClassificationIPC:A61K45/06, A61P35/00, A61K31/4184, A61K31/517, A61K31/5377, A61K31/519
[2017/52]
CPC:
A61K31/517 (EP,US); A61K31/166 (EP,US); A61K31/4184 (EP,US);
A61K31/5377 (EP,US); A61K45/06 (EP,US); A61P35/00 (EP,US)
C-Set:
A61K31/4184, A61K2300/00 (EP,US);
A61K31/517, A61K2300/00 (US,EP);
A61K31/5377, A61K2300/00 (US,EP)
Former IPC [2016/03]A61K45/06, A61P35/00, A61K31/4184, A61K31/517, A61K31/5377
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/03]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:KOMBINATIONEN AUS INHIBITOREN VON MEK, EGFR UND ERBB2 BEI DER BEHANDLUNG VON KRAS-MUTANTEM LUNGENKREBS[2017/50]
English:COMBINATIONS OF INHIBITORS OF MEK, EGFR AND ERBB2 IN THE TREATMENT OF KRAS-MUTANT LUNG CANCER[2017/50]
French:COMBINAISONS D'INHIBITEURS DE MEK, D'EGFR ET D'ERBB2 DANS LE TRAITEMENT DU CANCER DU POUMON À KRAS MUTANT[2017/50]
Former [2016/03]KOMBINATIONEN AUS INHIBITOREN VON MEK, EGFR UND ERBB2 BEI DER BEHANDLUNG VON KRAS-MUTANTEM LUNGENKREBS UND KRAS-MUTANTEM DICKDARMKREBS
Former [2016/03]COMBINATIONS OF INHIBITORS OF MEK, EGFR AND ERBB2 IN THE TREATMENT OF KRAS-MUTANT LUNG CANCER AND KRAS-MUTANT COLON CANCER
Former [2016/03]COMBINAISONS D'INHIBITEURS DE MEK, D'EGFR ET D'ERBB2 DANS LE TRAITEMENT DU CANCER DU POUMON À KRAS MUTANT ET DU CANCER DU CÔLON À KRAS MUTANT
Entry into regional phase12.10.2015National basic fee paid 
12.10.2015Designation fee(s) paid 
12.10.2015Examination fee paid 
Examination procedure12.10.2015Examination requested  [2016/03]
03.05.2016Amendment by applicant (claims and/or description)
02.08.2016Despatch of a communication from the examining division (Time limit: M06)
08.02.2017Reply to a communication from the examining division
07.11.2017Cancellation of oral proceeding that was planned for 04.12.2017
04.12.2017Date of oral proceedings (cancelled)
07.12.2017Communication of intention to grant the patent
15.12.2017Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
19.01.2018Communication of intention to grant the patent
18.05.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
13.06.2018Communication of intention to grant the patent
06.12.2018Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
04.02.2019Fee for grant paid
04.02.2019Fee for publishing/printing paid
04.02.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19173124.9  / EP3549584
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.08.2016
Opposition(s)11.02.2020No opposition filed within time limit [2020/16]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
04.02.2019Request for further processing filed
04.02.2019Full payment received (date of receipt of payment)
Request granted
18.02.2019Decision despatched
Fees paidRenewal fee
29.03.2016Renewal fee patent year 03
30.03.2017Renewal fee patent year 04
23.03.2018Renewal fee patent year 05
26.03.2019Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU12.03.2014
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
MK08.05.2019
MT08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
[2022/31]
Former [2022/30]HU12.03.2014
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
MT08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
Former [2022/27]HU12.03.2014
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
MT08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/50]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/25]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/17]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/14]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
SM08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/11]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/10]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/09]AL08.05.2019
CZ08.05.2019
DK08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/51]AL08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/50]AL08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
RS08.05.2019
SE08.05.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/49]AL08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
SE08.05.2019
NO08.08.2019
PT08.09.2019
Former [2019/48]FI08.05.2019
LT08.05.2019
SE08.05.2019
NO08.08.2019
PT08.09.2019
Former [2019/47]FI08.05.2019
LT08.05.2019
NO08.08.2019
Cited inInternational search[XP]  - "Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies (M13DAP)", (201401), ClinicalTrials.gov, URL: http://clinicaltrials.gov/ct2/show/NCT02039336?term=dacomitinib+and+pd0325901&rank=1, (20140604), XP002725340 [XP] 5,11 * the whole document *
 [I]  - H.-J. NAM ET AL, "Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer", MOLECULAR CANCER THERAPEUTICS, (20120201), vol. 11, no. 2, doi:10.1158/1535-7163.MCT-11-0494, ISSN 1535-7163, pages 439 - 451, XP055121073 [I] 1-18 * abstract * * page 447, column 1, paragraph 2 - page 448, column 1, paragraph 1 *

DOI:   http://dx.doi.org/10.1158/1535-7163.MCT-11-0494
 [I]  - HUA C. GONG ET AL, "Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer", INTERNATIONAL JOURNAL OF PROTEOMICS, (20110601), vol. 2011, doi:10.1155/2011/215496, ISSN 2090-2166, pages 1 - 13, XP055030274 [I] 1-18 * page 9, column 1, paragraph 2 - column 2 * * page 11, column 1, paragraph 2 - page 12 *

DOI:   http://dx.doi.org/10.1155/2011/215496
 [I]  - RODRIGO DIENSTMANN ET AL, "Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer", MOLECULAR ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 6, no. 1, doi:10.1016/J.MOLONC.2011.11.009, ISSN 1574-7891, (20111125), pages 15 - 26, (20111206), XP028452885 [I] 1-18 * abstract * * page 19, column 2, paragraph 3 - paragraph 4 *

DOI:   http://dx.doi.org/10.1016/j.molonc.2011.11.009
 [YP]  - KAREN L. RECKAMP ET AL, "A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib", CANCER, 05-02-14, (20140415), vol. 120, no. 8, doi:10.1002/cncr.28561, ISSN 0008-543X, pages 1145 - 1154, XP055121077 [YP] 1-18 * abstract *

DOI:   http://dx.doi.org/10.1002/cncr.28561
 [Y]  - ADI F GAZDAR, "Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DO, (20100203), vol. 29, no. 1, ISSN 1573-7233, pages 37 - 48, XP019787665 [Y] 1-18 * page 44, column 1, paragraph 2 - column 2, paragraph 1; table 1 *
 [I]  - HUANG MING-HUNG ET AL, "MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib", MOLECULAR ONCOLOGY, (201302), vol. 7, no. 1, pages 112 - 120, XP008165510 [I] 1-18 * abstract *

DOI:   http://dx.doi.org/10.1016/j.molonc.2012.09.002
 [Y]  - WALTERS DUSTIN M ET AL, "Inhibition of the Growth of Patient-Derived Pancreatic Cancer Xenografts with the MEK Inhibitor Trametinib Is Augmented by Combined Treatment with the Epidermal Growth Factor Receptor/HER2 Inhibitor Lapatinib", NEOPLASIA, NEOPLASIA PRESS, ANN ARBOR, MI, US, (201302), vol. 15, no. 2, doi:10.1593/NEO.121712, ISSN 1522-8002, pages 143 - 155, XP008165494 [Y] 1-18 * the whole document *

DOI:   http://dx.doi.org/10.1593/neo.121712
by applicantEP1877398
 EP2496575
 WO2012162561
    - BAST ET AL., Cancer Medicine, B. C. DECKER INC.
    - PRAHALLAD A ET AL., NATURE, (20120126), vol. 483, no. 7387, pages 100 - 3
    - PRIOR ET AL., CANCER RES, (2012), pages 2457 - 67
    - ADJEI, A.A.; COHEN, R.B.; FRANKLIN, W.; MORRIS, C.; WILSON, D.; MOLINA, J.R.; HANSON, L.J.; GORE, L.; CHOW, L.; LEONG, S. ET AL., "Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-1 42886) in patients with advanced cancers", J CLIN ONCOL, (2008), vol. 26, pages 2139 - 2146
    - "The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity", BARRETINA, J.; CAPONIGRO, G.; STRANSKY, N.; VENKATESAN, K.; MARGOLIN, A.A.; KIM, S.; WILSON, C.J.; LEHAR, J.; KRYUKOV, G.V.; SONKI, Nature, (2012), vol. 483, pages 603 - 607
    - BERNARDS, R., "A missing link in genotype-directed cancer therapy", CELL, (2012), vol. 151, pages 465 - 468
    - BONNI, A.; BRUNET, A.; WEST, A.E.; DATTA, S.R.; TAKASU, M.A.; GREENBERG, M.E., "Cell survival promoted by the Ras-MAPK signaling pathway by transcription- dependent and -independent mechanisms", SCIENCE, (1999), vol. 286, pages 1358 - 1362
    - BOS, J.L., "ras oncogenes in human cancer: a review", CANCER RES, (1989), vol. 50, no. 4, page 1352
    - CANCER RES, vol. 49, pages 4682 - 4689
    - CORCORAN, R.B.; CHENG, K.A.; HATA, A.N.; FABER, A.C.; EBI, H.; COFFEE, E.M.; GRENINGER, P.; BROWN, R.D.; GODFREY, J.T.; COHOON, T., "Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models", CANCER CELL, (2013), vol. 23, pages 121 - 128
    - DATTA, S.R.; DUDEK, H.; TAO, X.; MASTERS, S.; FU, H.; GOTOH, Y.; GREENBERG, M.E., "Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery", CELL, (1997), vol. 91, pages 231 - 241
    - FLAHERTY, K.T.; INFANTE, J.R.; DAUD, A.; GONZALEZ, R.; KEFFORD, R.F.; SOSMAN, J.; HAMID, O.; SCHUCHTER, L.; CEBON, J.; IBRAHIM, N., "Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations", N ENGL J MED, (2012), vol. 367, pages 1694 - 1703
    - FLAHERTY, K.T.; PUZANOV, I.; KIM, K.B.; RIBAS, A.; MCARTHUR, G.A.; SOSMAN, J.A.; O'DWYER, P.J.; LEE, R.J.; GRIPPO, J.F.; NOLOP, K., "Inhibition of mutated, activated BRAF in metastatic melanoma", N ENGL J MED, (2010), vol. 363, pages 809 - 819
    - GARNETT, M.J.; EDELMAN, E.J.; HEIDORN, S.J.; GREENMAN, C.D.; DASTUR, A.; LAU, K.W.; GRENINGER, P.; THOMPSON, I.R.; LUO, X.; SOARES, "Systematic identification of genomic markers of drug sensitivity in cancer cells", NATURE, (2012), vol. 483, pages 570 - 575
    - HARADA, H.; QUEARRY, B.; RUIZ-VELA, A.; KORSMEYER, S.J., "Survival factor- induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity", PROC NATL ACAD SCI U S A, (2004), vol. 101, pages 15313 - 15317
    - JANNE, P.A.; SHAW, A.T.; PEREIRA, J.R.; JEANNIN, G.; VANSTEENKISTE, J.; BARRIOS, C.; FRANKE, F.A.; GRINSTED, L.; ZAZULINA, V.; SMI, "Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study", LANCET ONCOL, (2013), vol. 14, pages 38 - 47
    - KWAK, E.L.; BANG, Y.J.; CAMIDGE, D.R.; SHAW, A.T.; SOLOMON, B.; MAKI, R.G.; OU, S.H.; DEZUBE, B.J.; JANNE, P.A.; COSTA, D.B. ET AL, "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", N ENGL J MED, (2010), vol. 363, pages 1693 - 1703
    - LYNCH, T.J.; BELL, D.W.; SORDELLA, R.; GURUBHAGAVATULA, S.; OKIMOTO, R.A.; BRANNIGAN, B.W.; HARRIS, P.L.; HASERLAT, S.M.; SUPKO, J, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N ENGL J MED, (2004), vol. 350, pages 2129 - 2139
    - MIGLIARDI, G.; SASSI, F.; TORTI, D.; GALIMI, F.; ZANELLA, E.R.; BUSCARINO, M.; RIBERO, D.; MURATORE, A.; MASSUCCO, P.; PISACANE, A, "Inhibition of MEK and P13K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas", CLIN CANCER RES, (2012), vol. 18, pages 2515 - 2525
    - PRAHALLAD, A.; SUN, C.; HUANG, S.; DI NICOLANTONIO, F.; SALAZAR, R.; ZECCHIN, D.; BEIJERSBERGEN, R.L.; BARDELLI, A.; BERNARDS, R., "Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR", NATURE, (2012), vol. 483, pages 100 - 103
    - PYLAYEVA-GUPTA, Y.; GRABOCKA, E.; BAR-SAGI, D., "RAS oncogenes: weaving a tumorigenic web", NATURE REVIEWS, (2011), vol. 11, pages 761 - 774
    - SCHEID, M.P.; SCHUBERT, K.M.; DURONIO, V., "Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase", J BIOL CHEM, (1999), vol. 274, pages 31108 - 31113
    - SEARS, R.; LEONE, G.; DEGREGORI, J.; NEVINS, J.R., "Ras enhances Myc protein stability", MOL CELL, (1999), vol. 3, pages 169 - 179
    - SEARS, R.; NUCKOLLS, F.; HAURA, E.; TAYA, Y.; TAMAI, K.; NEVINS, J.R., "Multiple ras-dependent phosphorylation pathways regulate myc protein stability", GENES DEV, (2000), vol. 14, pages 2501 - 2514
    - SITHANANDAM, G.; ANDERSON, L.M., "The ERBB3 receptor in cancer and cancer gene therapy", CANCER GENE THERAPY, (2008), vol. 15, pages 413 - 448
    - SUEN, T.C.; HUNG, M.C., "c-myc reverses neu-induced transformed morphology by transcriptional repression", MOL CELL BIOL, (1991), vol. 11, pages 354 - 362
    - WANG, J.; KIM, J.; ROH, M.; FRANCO, O.E.; HAYWARD, S.W.; WILLS, M.L.; ABDULKADIR, S.A., "Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma", ONCOGENE, (2010), vol. 29, pages 2477 - 2487
    - WEINSTEIN, I.B., "Cancer. Addiction to oncogenes--the Achilles heal of cancer", SCIENCE, (2002), vol. 297, pages 63 - 64
    - ZHA, J.; HARADA, H.; YANG, E.; JOCKEL, J.; KORSMEYER, S.J., "Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L", CELL, (1996), vol. 87, pages 619 - 628
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.